Replies to post #243465 on Biotech Values

[Biowatch]

I think they would license and outsource as much as possible and not try to manufacture drugs on a large scale.

Mind you, something like patient specific CAR-T therapy can be done in house, as it tends to be one or two incubators entirely devoted to a particular patient, and rarely scales up much larger than that.

https://www.mskcc.org/research-advantage/support/office-technology-development